UPDATE: Rexahn Says Results of Data form Supinoxin, RX-3117 Programs Showed Oral Administration of Supinoxin Appeared Safe, Well Tolerated with No Grade 3 or 4 Adverse Events, Only One Unrelated Grade 2 Event